UK techbio company Scripta Therapeutics has announced it has raised $12 million to find disease-modifying drugs altering transcription factor activity.  The financing round was led by by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advisors, with support from Oxford University Innovation.  Scripta’s approach combines AI, imaging, and patient-derived models […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!